Cantor Fitzgerlad



Cantor Fitzgerlad Recent News

Jushi Holdings Will Soon Announce 3Q, Analyst Puts Price Target At $2.25 And Maintains Neutral Rating
Green Thumb Industries Among Top Cannabis MSO Stocks Ahead Of Earnings Season, Analyst Tells Us Why
Is Aurora Cannabis' 'Business Transformation Plan' Yielding Results?
Cantor Remains Neutral On Aleafia Health, Lowers Price Target On Sectoral Derating, Sees Value
Aphria One Step Closer To Merging With Tilray, Shareholders Overwhelmingly Approve The Deal
Cantor Analyst Raises Aphria And Tilray Price Targets Amid Merger
Analyst: Here Are The Latest Cannabis MSO Trends In IL, MA, NV And FL
Cantor Fitzgerald Lowers GW Pharmaceuticals Price Target
What Do Zogenix Drug Study Results Mean For GW Pharmaceuticals' Epidiolex?
Clearing Up Misconceptions Surrounding Aerie Pharmaceuticals
Internet Stocks Outperformed The Market During Brexit Week
Cantor Fitzgerald Initiates The Rubicon Project With Buy Rating, $22 Target
Is Yahoo In A Win-Win-Win Situation?
Cantor Still Expects Threshold Pharma To More Than Triple, Says 2016 Will Be 'Data Rich' Year
Cantor Reiterates Buy On LinkedIn, Issues 'Clearing Up'
Cantor Downgrades Lumber Liquidators, Slashes Targets On 'Too Many' Risks
What Could Be Coming For Cisco, According To Cantor Fitzgerald
Wall Street Voices Opinion On Apple Watch
Does AOL's New Ad Platform Make It A Buy?
Oracle Primed To Leverage New Cloud Solutions, Says Cantor Fitzgerald
Apple At $180? This Analyst Thinks So
Netflix Is The 'Clear Winner' As Trend Of TV Bundling Grows Stronger
Cantor Fitzgerald Expects LinkedIn's Q4 Report To Show 'Continued Business Momentum'